Author: Tely Publisher

Introduction

The classification of medical devices under the European Union Medical Device Regulation (EU MDR) is a critical component of ensuring safety and efficacy in healthcare. This structured methodology categorizes devices based on their intended use and associated risk levels, influencing everything from regulatory scrutiny to post-market surveillance obligations.

With the EU MDR delineating three primary categories—Class I, Class II, and Class III—manufacturers, regulatory authorities, and healthcare professionals must navigate a complex framework that directly impacts market access and compliance.

As the landscape evolves, particularly with the impending deadlines for compliance and the heightened scrutiny of high-risk devices, understanding the nuances of this classification system becomes essential for all stakeholders involved in the medical device lifecycle.

Understanding Medical Device Classification Under EU MDR

under the represents a structured methodology that categorizes according to their intended use and associated risk levels. This categorization system is vital for ensuring that medical products comply with strict safety and efficacy criteria before entering the market. The EU MDR outlines a framework for that categorizes products into three primary groups:

1. Class I

Each group has specific regulatory obligations.

The not only determines the intensity of scrutiny a product faces during its approval process but also significantly affects and compliance responsibilities. In Colombia, the regulation of falls under the jurisdiction of (Colombia National Food and Drug Surveillance Institute), which is responsible for inspecting and supervising the marketing and production of health products. The Directorate for and other Technologies plays a crucial role within , monitoring and controlling healthcare tools, suggesting technical standards, and ensuring compliance with pre- and post-market requirements.

As a Level 4 health authority recognized by the Pan American Health Organization/World Health Organization, ensures that healthcare products meet high safety, efficacy, and quality standards. Navigating the is essential for manufacturers, regulatory bodies, and healthcare experts, as it directly impacts the development, approval, and market access of healthcare products. As Saint-Gobain states, ‘,’ emphasizing the importance of support in this complex landscape.

Moreover, the recent case study concerning emphasizes the urgency for manufacturers to adhere to IVDR requirements by the deadline of 26 May 2025, especially considering potential public health risks due to shortages of in vitro diagnostic products. This situation underscores ‘s role in ensuring compliance and safety for medical devices in the Colombian market. Furthermore, with four applications chosen as test cases for the first phase of the pilot, this statistic illustrates the sorting process in action.

As new regulations unfold, awareness of the is crucial for maintaining compliance and ensuring patient safety.

Exploring Classifications: Class I, II, and III Medical Devices

(MDR) categorizes medical instruments into three distinct classes: Class I, Class II, and Class III. Class I products, deemed low risk, typically include everyday items like bandages and non-invasive instruments, requiring minimal regulatory oversight. Producers of these products often appreciate the ability to self-certify adherence to applicable regulations.

In contrast, , which present a moderate risk, cover a wider array of products, such as infusion pumps and diagnostic imaging equipment. These instruments require a more comprehensive oversight assessment, including evaluations by designated organizations to ensure safety and effectiveness. signify the highest risk category, including implantable items such as pacemakers and prosthetics, subjected to the most stringent oversight demanding comprehensive and continuous post-market clinical follow-up (PMCF) to confirm safety and performance.

As noted by Laura Court, ‘A successful clinical evaluation report hinges on the quality of and the processes for collecting and analyzing it.’ Furthermore, the importance of ongoing updates is illustrated by the , which must be updated annually for implantable Class III devices, incorporating findings from PMCF and PSUR. This governance framework is crucial for ensuring patient safety and enhancing healthcare efficiency, as evidenced by the statistic that

A comprehensive grasp of these categories, along with bioaccess®‘s expertise in handling , , Pilot Studies, Pivotal Studies, and , is crucial for manufacturers to maneuver the intricate compliance framework and ensure adherence to the medical device classification MDR. Bioaccess® offers extensive services, including feasibility studies, site selection, and compliance reviews, all directed by the expertise of Katherine Ruiz in Regulatory Affairs for healthcare products and in vitro diagnostics in Colombia.

Determining Risk Classification for Medical Devices

Establishing the requires a comprehensive assessment of various elements, such as the instrument’s intended purpose, length of contact with the body, and the related potential hazards. Manufacturers are tasked with assessing aspects such as design, materials, and mode of action to accurately determine categorization. According to the EU MDR, are available to support manufacturers through classification MDR process, particularly the categorization rules detailed in Annex VIII of the regulation, which outline the criteria for determining whether an item falls into Class I, IIa, IIb, or III based on its risk profile and intended use.

For instance, instruments intended for invasive procedures generally fall into compared to non-invasive counterparts. This categorization under the is not merely procedural; it significantly influences the regulatory pathway, dictating the type of clinical data required for approval and the extent of oversight necessary during post-market surveillance. As emphasized by Murugan Kandasamy, Managing Director & CEO at DQS India, ‘Nonetheless, maneuvering through the categorization route can be difficult, especially for intricate or novel healthcare instruments.’

This emphasizes the critical nature of the risk categorization process, which ultimately aims to enhance patient safety and ensure compliance with current regulations. Furthermore, in 2023, certificated Class III health products constituted 11% of items recorded in EUDAMED, illustrating the ongoing importance of rigorous classification standards in the healthcare landscape. A crucial document in this context is the , which serves as a mandatory component for all healthcare products sold in the EU, detailing the essential for demonstrating safety and performance.

The CER must be comprehensive and cross-referenced with supporting documents to ensure compliance with EU regulations. Furthermore, healthcare equipment producers must follow specific MDR to ensure safe and effective use, which further underscores the significance of adherence within the compliance framework. Our comprehensive support manufacturers through:

1. Feasibility studies
2. Site selection
3. Compliance reviews
4. Trial setup
5. Import permits
6. Project management
7. Reporting

By integrating these services, we enhance the , ensuring that products meet the necessary safety and performance criteria while navigating the complexities of .

Four Steps to Classify a Medical Device Under EU MDR

involves a structured process for classifying a healthcare instrument under the EU Medical Equipment Regulation, consisting of four essential steps designed to ensure compliance and facilitate market access. The EU MDR document itself is extensive, comprising 10 Chapters, 123 Articles, 17 Annexes, and a total of 175 pages, reflecting the complexity of the regulations governing medical equipment. These steps are as follows:

1. Identify the : The first step involves a precise definition of the item’s purpose and the specific patient population it targets. This clarity is critical as it informs subsequent evaluations and regulatory requirements.
2. Evaluate the Equipment Characteristics: Manufacturers must assess the design, materials, and technological features of the equipment to establish its . This evaluation is vital to understanding how the instrument may interact with patients and the environment.
3. : to ascertain the suitable class for the item based on its and features according to the . Grasping the categorization is crucial, as it determines the that need to be fulfilled. As Bruna De Lucca Caetano rightly points out, understanding the categorization of a healthcare instrument is crucial since it determines the that such instruments must meet. Notably, within Class I, there are three sub-classifications that require notified body involvement: Class Is (sterile), Class Im (measuring feature), and Class Ir (reusable surgical instrument).
4. Document the Classification Decision: Comprehensive documentation is crucial in this step. Manufacturers should keep detailed records of their sorting process, including justifications for the chosen categorization. This documentation not only aids in but also equips the manufacturer for possible evaluations.

Ana Criado, our Director of Compliance Affairs and a seasoned expert in the field, emphasizes the significance of these steps in ensuring that medical products meet the and fulfill the necessary requirements for while promoting safety and efficacy. Drawing on her extensive experience at INVIMA, where she navigated complex regulatory frameworks, Ana highlights that a thorough understanding of the classification process is essential for compliance and effective . Additionally, the , which Ana emphasizes is crucial for ongoing data collection and assessment to ensure safety and efficacy. Her insights highlight the significance of systematic documentation practices, especially as deadlines for compliance near, such as the requirement for Class III custom-made implantable items to comply by May 26, 2026.

Navigating the Implications of MDR Classification for Manufacturers

of healthcare products under the EU MDR carries significant implications for producers, dictating specific , post-market monitoring, and . Our comprehensive include:

1. Feasibility studies
2. Site selection
3. Compliance reviews
4. Trial setup
5. Import permits
6. Project management
7. Reporting

This ensures that all aspects of the process are meticulously handled. Specifically, we provide review and feedback on study documents to comply with country requirements and detailed reporting on study status, inventory, and both serious and non-serious adverse events.

Notably, 69% of participants in a recent analysis were categorized into the ”, underscoring the heightened scrutiny faced by these manufacturers. For instance, while Class I products may face fewer compliance challenges, those involved in the for Class III items must manage and continuous oversight, which can be resource-intensive. Katherine Ruiz, a specialist in compliance matters for medical instruments and in vitro diagnostics in Colombia, highlights the , stating, ‘Having the right tools in place for QMS and documentation is a crucial success factor for the time to product marketing and thus for the business success of your company.’

Furthermore, a recent survey revealed that 83.3% of large enterprises believe , highlighting the perceived benefits despite the challenges. Manufacturers must remain vigilant regarding updates to the EU MDR related to , as failure to comply can result in severe penalties, including market withdrawal. indicate a recognition of these challenges, allowing more time for manufacturers and notified bodies to certify devices amidst concerns about supply shortages. The re-certification of existing products has emerged as a significant challenge, compelling manufacturers to undertake extensive documentation updates and follow stricter compliance standards. This process often requires systematic reviews of existing products against the requirements and early engagement with Notified Bodies to streamline re-certification procedures.

Understanding these implications enables manufacturers to strategically navigate the regulatory landscape, ensuring successful market entry and sustained compliance.

Conclusion

The classification of medical devices under the EU Medical Device Regulation (MDR) is a pivotal aspect of ensuring safety, efficacy, and compliance within the healthcare sector. By categorizing devices into Classes I, II, and III based on their intended use and associated risks, the regulation establishes a clear framework that guides manufacturers through the complexities of market access and regulatory obligations. Each class presents distinct challenges and requirements, highlighting the critical nature of understanding the nuances involved in the classification process.

As the landscape of medical device regulation evolves, particularly with impending deadlines for compliance, stakeholders—including manufacturers, regulatory authorities, and healthcare professionals—must prioritize their understanding of these classifications. The implications of classification extend beyond initial approval; they encompass ongoing post-market surveillance, quality management systems, and compliance with stringent documentation practices. This comprehensive awareness is essential not only for meeting regulatory expectations but also for ensuring patient safety and maintaining public trust in medical technologies.

In conclusion, navigating the intricacies of the EU MDR classification system is essential for all parties involved in the medical device lifecycle. By adhering to the established guidelines and remaining proactive in compliance efforts, stakeholders can effectively mitigate risks, enhance product safety, and ultimately contribute to improved healthcare outcomes. The commitment to understanding and applying these regulations will foster an environment of innovation and reliability in the medical device market, ensuring that high standards are upheld for the benefit of patients and healthcare providers alike.

Stay ahead of the curve—contact bioaccess™ today to learn how our expert CRO services can help you navigate the complexities of medical device regulations in Latin America!

Frequently Asked Questions

What is the purpose of the medical device classification under the EU MDR?

The medical device classification under the EU MDR categorizes healthcare instruments according to their intended use and associated risk levels, ensuring compliance with strict safety and efficacy criteria before products enter the market.

What are the three primary classes of medical devices according to the EU MDR?

The three primary classes of medical devices are Class I, Class II, and Class III, each with specific regulatory obligations.

How does the classification of a medical device affect its approval process?

The classification determines the intensity of scrutiny a product faces during its approval process and significantly affects post-market surveillance and compliance responsibilities.

What role does INVIMA play in the regulation of healthcare instruments in Colombia?

INVIMA, the Colombia National Food and Drug Surveillance Institute, is responsible for inspecting and supervising the marketing and production of health products, ensuring that they meet high safety, efficacy, and quality standards.

What are the characteristics of Class I medical devices?

Class I medical devices are deemed low risk and include everyday items like bandages and non-invasive instruments, requiring minimal regulatory oversight and allowing producers to self-certify compliance.

What types of products fall under Class II medical devices?

Class II medical devices present a moderate risk and include products such as infusion pumps and diagnostic imaging equipment, requiring more comprehensive oversight and evaluations by designated organizations.

What distinguishes Class III medical devices from the other classes?

Class III medical devices signify the highest risk category, including implantable items like pacemakers and prosthetics, and are subjected to the most stringent oversight, requiring comprehensive clinical data and continuous post-market clinical follow-up.

What is the importance of the Summary of Safety and Clinical Performance (SSCP)?

The SSCP must be updated annually for implantable Class III devices, incorporating findings from post-market clinical follow-up and ensuring ongoing compliance with safety and performance standards.

How can manufacturers navigate the medical device classification framework?

Manufacturers can navigate the framework by understanding the classifications, utilizing services for feasibility studies, site selection, and compliance reviews, and leveraging expertise in regulatory affairs.

What is the deadline for manufacturers to adhere to IVDR requirements as per Regulation (EU) 2024/1860?

Manufacturers must adhere to IVDR requirements by the deadline of 26 May 2025, highlighting the urgency for compliance due to potential public health risks.

List of Sources

1. Understanding Medical Device Classification Under EU MDR
   • mdrregulator.com (https://mdrregulator.com/news/regulation-eu-2024-1860-the-latest-changes-to-mdr-and-ivdr)
   • medical.saint-gobain.com (https://medical.saint-gobain.com/resources/blog/eu-mdr-what-it-and-why-it-necessary)
   • ema.europa.eu (https://ema.europa.eu/en/human-regulatory-overview/medical-devices)
2. Exploring Classifications: Class I, II, and III Medical Devices
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10062684)
   • greenlight.guru (https://greenlight.guru/blog/device-class-requirements-eu-mdr)
3. Determining Risk Classification for Medical Devices
   • simplerqms.com (https://simplerqms.com/eu-mdr-medical-device-classification)
   • greenlight.guru (https://greenlight.guru/blog/device-class-requirements-eu-mdr)
   • dqsglobal.com (https://dqsglobal.com/en-us/learn/blog/understanding-the-classification-of-medical-devices-under-eu-mdr)
4. Four Steps to Classify a Medical Device Under EU MDR
   • medical.saint-gobain.com (https://medical.saint-gobain.com/resources/blog/eu-mdr-what-it-and-why-it-necessary)
   • greenlight.guru (https://greenlight.guru/blog/device-class-requirements-eu-mdr)
   • greenlight.guru (https://greenlight.guru/blog/eu-medical-device-classification)
   • simplerqms.com (https://simplerqms.com/eu-mdr-medical-device-classification)
5. Navigating the Implications of MDR Classification for Manufacturers
   • matrixreq.com (https://matrixreq.com/blog/navigating-the-european-union-s-medical-device-regulation-mdr-challenges-and-crucial-aspects-for-manufacturers)
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10276779)
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10062684)

Introduction

Contract Research Organizations (CROs) play a vital role in advancing medical research. With their expertise in clinical trials, data management, and regulatory compliance, CROs offer researchers access to specialized skills and state-of-the-art facilities.

This collaboration can significantly enhance the efficiency and success rate of clinical endeavors while addressing complex ethical, legal, and social challenges. As the medical community continues to tackle global diseases, the strategic partnership with CROs becomes increasingly essential in improving patient outcomes and advancing medical science. In this article, we will explore the importance of CRO services in medical research, the challenges faced, successful case studies, the benefits of data-driven results, and best practices for effective collaboration with CRO services.

The Importance of CRO Services in Medical Research

are pivotal in advancing clinical research, providing a suite of services that propel studies from conception to conclusion. They bring a wealth of expertise in navigating the intricate landscape of , managing vast datasets, and upholding stringent regulatory standards.

Collaborating with CROss offers researchers access to , which can markedly boost the efficiency and success rate of clinical endeavors. Moreover, the complex ethical, legal, and social challenges that surface in the development of emerging technologies.

They help delineate clear, —tailoring their services to meet the precise needs of the research while leveraging internal resources effectively. The 2023 Perceptions and Insights Study by CISCRP underscores the critical role of research professionals in patient engagement and the broader mission of enhancing . As the medical community continues to tackle diseases on a global scale, the strategic partnership with CROs becomes increasingly essential, ensuring that the social goals of research are met and that every study is a step toward improving the human condition.

Challenges Faced in Medical Research and the Role of CRO Services

Navigating the complexities of , especially for rare diseases, requires meticulous planning and precise execution. The challenge is amplified when patient populations are scarce and dispersed, as illustrated by a patient in rural Pennsylvania with an ultra-rare condition contemplating participation in a clinical trial in Turkey. This scenario underscores not only the logistical hurdles of cross-border travel but also the intricate web of that must be delicately balanced.

A becomes instrumental in these instances, offering a network of investigators and research sites that can bridge the geographical and regulatory divides. By adopting a SMART approach to define specific, measurable, attainable, relevant, and time-bound requirements, CROss can tailor their services to the unique needs of a study, ensuring that resources are optimized and that any in-house capabilities are effectively leveraged. Moreover, CROss are positioned to address the Question(s) of Interest and Context of Use, ensuring that the computational models and other sources of information are aligned with the regulatory submission’s objectives.

The value of a CRO in this setting is multi-faceted. They ensure adherence to the evolving international legal and regulatory landscape, address the social goals of the research aimed at , and consider the technology’s ethical implications. This not only enhances the reliability of research outcomes but also resonates with a broad spectrum of stakeholders, including researchers, advocacy groups, federal agencies, and investors, all of whom are invested in the advancement of medical science for both rare and common diseases.

Case Study: Successful Implementation of CRO Services in Medical Research

A medical research organization aiming to pioneer a for an innovative therapy encountered the intricate . With across its nations, where public, private, and social security services intertwine, successful navigation of this environment is critical.

To address this challenge, the organization collaborated with a (CRO) well-versed in the region’s . This partnership was pivotal in steering through the regulatory complexities, as Latin America’s healthcare systems, though offering basic cancer care, often present , and variability in service availability is common.

The CRO’s expertise in primary research, evidence synthesis, and policy analysis, akin to the skills highlighted by Kati from Economist Impact, was instrumental in site selection and ensuring the trial adhered to regulatory and ethical standards. As a result, the trial was executed efficiently, meeting the required timelines and contributing to the collective advancement of medical science in the region. This case exemplifies the practical application of implementation science and the importance of leveraging local knowledge and scientific evidence to enhance the quality and safety of , as noted in the study published in Enfermagem 2023.

Benefits of CRO Services: Data-Driven Results and Insights

are pivotal in advancing through their meticulous . By employing these strengths, CROss not only ensure the accuracy and integrity of data collection but also enhance the analysis, driving insights that guide informed decision-making. The 2023 Perceptions and Insights Study by CISCRP highlights the significance of research professionals in , recruitment, and retention, emphasizing the human element in clinical trials.

CROss contribute to this by providing access to extensive patient databases, which enhances the studied and strengthens the external validity of research outcomes. As research teams, often operating with limited internal resources, focus on defining their specific, measurable, attainable, relevant, and time-bound (SMART) requirements, CROss can offer tailored services that fill gaps and complement in-house capabilities. This symbiotic relationship between research professionals and CROss is essential in fostering the collective aim of on both individual and community levels.

Best Practices for Effective Collaboration with CRO Services

Enhancing research outcomes through collaboration with necessitates a strategic approach that is both systematic and adaptive. To achieve this, researchers must first delineate their requirements using the SMART framework—ensuring goals are Specific, Measurable, Attainable, Relevant, and Time-bound.

This precision in planning allows for a clear presentation of needs, leading to accurate proposals and . Furthermore, it is imperative to assess which aspects of the research can be managed internally, considering the lean nature of many .

The collaboration should be characterized by open communication, fostering an environment where updates are exchanged regularly, and any arising challenges are promptly addressed. This is in line with the principles of , which is known to yield more comprehensive solutions by integrating various areas of expertise, such as medicine, engineering, and social sciences.

An established , which includes detailed timelines, milestones, and deliverables, is essential to maintaining a streamlined research process and navigating the complex landscape of . A successful partnership with a CRO also hinges on a transparent and cooperative relationship, underpinned by mutual trust and shared objectives. By leveraging the diverse perspectives and expertise of all parties involved, research can transcend traditional boundaries, leading to impactful healthcare innovations that consider medical efficacy, user experience, and psychological well-being. The importance of such collaboration is further emphasized by contributions to policy, influences on care practices, and the development of health services and products, as evidenced by such as the ELSA study funded by Diabetes UK and the Juvenile Diabetes Research Foundation.

Conclusion

In conclusion, Contract Research Organizations (CROs) are vital in advancing medical research. They bring expertise in clinical trials, data management, and regulatory compliance, enhancing efficiency and success rates. Collaborating with CROs provides access to specialized skills and facilities, essential for tackling global diseases and improving patient outcomes.

CROs navigate the complexities of clinical research, especially for rare diseases and dispersed patient populations. Their SMART approach tailors services to study needs, optimizing resources and ensuring regulatory alignment. Successful case studies showcase CRO services overcoming regulatory complexities, accelerating trials, and contributing to medical science advancement.

Data-driven results and insights from meticulous data management enhance decision-making and strengthen research outcomes. Effective collaboration with CROs requires strategic planning, open communication, interdisciplinary collaboration, and a project management plan. Transparent relationships based on trust and shared objectives drive successful partnerships.

In summary, researchers partnering with CROs advance medical research by leveraging specialized skills and data-driven insights. This collaboration is crucial for addressing complex challenges while improving patient outcomes. By optimizing resources and navigating regulatory complexities, CROs play a pivotal role in advancing medical science on a global scale.

Ready to collaborate with Bioaccess™ and leverage our specialized skills and facilities to advance medical research and improve patient outcomes? Contact us now!

Frequently Asked Questions

What are Contract Research Organizations (CROs)?

CROs are specialized organizations that provide a suite of services to advance clinical research, managing various aspects of studies from conception to conclusion while ensuring compliance with regulatory standards.

How do CROs enhance the efficiency of clinical trials?

CROs bring expertise in navigating the complexities of clinical trials, managing large datasets, and addressing ethical, legal, and social challenges, which significantly boosts the efficiency and success rates of research endeavors.

What is the SMART framework mentioned in the article?

The SMART framework refers to setting objectives that are Specific, Measurable, Attainable, Relevant, and Time-bound. This approach helps CROs tailor their services to meet the precise needs of research projects.

What challenges do CROs help address in medical research?

CROs help navigate logistical hurdles, especially in scenarios involving rare diseases and dispersed patient populations. They also ensure adherence to evolving international regulations and address the ethical implications of research.

Can you provide an example of CRO services in action?

The article discusses a case where a medical research organization collaborated with a CRO to navigate the complex regulatory landscape in Latin America for a clinical trial. The CRO’s local expertise facilitated efficient execution and adherence to standards, showcasing the practical application of CRO services.

What benefits do CROs offer in data management?

CROs enhance data accuracy and integrity through meticulous management and statistical analysis, driving insights that inform decision-making and improve patient engagement and recruitment in clinical trials.

How do CROs contribute to patient diversity in research?

CROs provide access to extensive patient databases, which enrich the diversity of patient populations involved in studies, thus strengthening the external validity of research outcomes.

What best practices should researchers follow when collaborating with CROs?

Researchers should clearly define their requirements using the SMART framework, maintain open communication, develop a project management plan with timelines and milestones, and foster a transparent, cooperative relationship with CROs.

Why is collaboration with CROs increasingly essential in medical research?

As the medical community addresses diseases on a global scale, CROs play a vital role in ensuring that research meets social goals and contributes to improving the human condition through effective and efficient clinical studies.

List of Sources

1. The Importance of CRO Services in Medical Research
   • medhealthoutlook.com (https://medhealthoutlook.com/three-best-practices-to-combat-clinical-trial-pain-points-scott-gray-ceo-of-clincierge/)
   • ctsi.umn.edu (https://ctsi.umn.edu/news/rewards-being-research-professional)
   • nam.edu (https://nam.edu/regenerative-medicine-case-study-for-understanding-and-anticipating-emerging-science-and-technology/)
   • greenlight.guru (https://www.greenlight.guru/blog/outsourcing-clinical-activities-in-2024-choosing-a-cro)
2. Challenges Faced in Medical Research and the Role of CRO Services
   • starfishmedical.com (https://starfishmedical.com/blog/fda-guidance-on-cms-in-medical-device-submissions/)
   • medhealthoutlook.com (https://medhealthoutlook.com/three-best-practices-to-combat-clinical-trial-pain-points-scott-gray-ceo-of-clincierge/)
   • greenlight.guru (https://www.greenlight.guru/blog/outsourcing-clinical-activities-in-2024-choosing-a-cro)
   • nih.gov (https://www.nih.gov/about-nih/what-we-do/science-health-public-trust/perspectives/communicating-about-rare-diseases?utm_source=Twitter&utm_medium=Social&utm_campaign=RD+blog+post)
   • nam.edu (https://nam.edu/regenerative-medicine-case-study-for-understanding-and-anticipating-emerging-science-and-technology/)
   • nih.gov (https://www.nih.gov/about-nih/what-we-do/science-health-public-trust/perspectives/communicating-about-rare-diseases?utm_source=Twitter&utm_medium=Social&utm_campaign=RD+blog+post)
   • insights.axtria.com (https://insights.axtria.com/articles/modeling-the-difficult-to-model-disease-considerations-for-evaluating-the-cost-effectiveness-in-rare-diseases)
3. Case Study: Successful Implementation of CRO Services in Medical Research
   • pubmed.ncbi.nlm.nih.gov (https://pubmed.ncbi.nlm.nih.gov/37533928)
   • impact.economist.com (https://impact.economist.com/perspectives/health/one-stripe-time-raising-awareness-rare-diseases-latin-america)
   • scielo.br (https://www.scielo.br/j/rlae/a/vCqYCxtvTL8FmFpKnsGgh4r/?format=pdf&lang=es)
4. Benefits of CRO Services: Data-Driven Results and Insights
   • ctsi.umn.edu (https://ctsi.umn.edu/news/rewards-being-research-professional)
   • greenlight.guru (https://www.greenlight.guru/blog/outsourcing-clinical-activities-in-2024-choosing-a-cro)
5. Best Practices for Effective Collaboration with CRO Services
   • researchfish.com (https://researchfish.com/blog/research-characteristics-collaboration/?utm_source=Organic-Social&utm_medium=Twitter&utm_campaign=Q423-RF-Research-Characteristics___)
   • cihr-irsc.gc.ca (https://cihr-irsc.gc.ca/e/53702.html)
   • transforming-evidence.org (https://transforming-evidence.org/blog/policy-evaluations-better-together)
   • greenlight.guru (https://www.greenlight.guru/blog/outsourcing-clinical-activities-in-2024-choosing-a-cro)
   • ashecon.org (https://www.ashecon.org/activities/news/sharing-your-research-for-maximum-impact/)
   • gov.uk (https://www.gov.uk/government/publications/research-collaboration-advice-team-progress-made-from-2022-to-2023/research-collaboration-advice-team-progress-made-from-2022-to-2023)
   • atlantbh.com (https://www.atlantbh.com/crafting-collaboration-in-elixir-a-case-study-of-success-in-software-development/)
   • nhsconfed.org (https://www.nhsconfed.org/publications/collaborate-innovate)

Introduction

In the dynamic landscape of clinical research, navigating the regulatory framework in Peru is crucial for researchers aiming to conduct successful trials. Governed by the National Institute of Health, the approval and oversight of clinical studies in Peru involve a complex interplay of laws, ethics, and compliance measures.

Understanding the following is essential for ensuring patient safety and maintaining public trust:

1. The Clinical Trials Law
2. The role of ethics committees
3. The submission process

With recent updates aimed at streamlining these processes, researchers must stay informed to leverage opportunities for efficient trial initiation.

This article delves into key strategies for optimizing clinical trial management in Peru, including:

• Selecting the right sites
• Engaging local stakeholders
• Incorporating cultural insights

Ultimately, these strategies enhance the likelihood of successful outcomes in this vibrant market.

Navigate Peru’s Regulatory Framework for Clinical Trials

Peru’s research study environment is primarily governed by the National Institute of Health (INS), which holds the responsibility for the authorization and oversight of research investigations. Researchers must navigate several key regulations to ensure compliance:

• : This law establishes the framework for conducting research studies, emphasizing ethical considerations and safety protocols for participants. Ratified through Supreme Decree No 021-2017-SA, it lays the groundwork for in the country. The implications of this regulation encompass stringent requirements for ethical oversight and , which are essential for maintaining public trust in clinical research.
• : All clinical studies require review and approval from an accredited ethics committee. This step is crucial for safeguarding the rights and well-being of participants, ensuring that ethical standards are upheld throughout the research process.
• : Researchers must submit comprehensive documentation, including detailed protocols, informed consent forms, and safety reporting plans, to the INS for approval prior to commencing any study. This process is designed to ensure that all aspects of the examination are thoroughly vetted for compliance with regulatory standards.

Recent updates to the in 2025 have introduced new guidelines aimed at streamlining the approval procedure, potentially reducing timelines for initiation. Staying informed about these changes is vital for researchers looking to implement in Peru. For instance, has effectively utilized its expertise in navigating these regulations, particularly concerning the and collaboration with . Furthermore, offers extensive services, including feasibility assessments, site selection, and project management, which support in Peru, enhancing the likelihood of and expediting the path to commercialization for innovative Medtech solutions. Additionally, ‘s commitment to data protection ensures that client concerns are addressed with compliance and transparency, bolstering confidence in the research process. It is also important to note that investigational products may be used under post-study access if they have benefited the research subject, as determined by the principal investigator, adding another layer of consideration for researchers within the regulatory landscape.

Choose Optimal Clinical Sites for Your Trials in Peru

Selecting clinical trial sites in Peru necessitates a meticulous evaluation of several pivotal factors to guarantee .

• Site Experience: It is imperative to prioritize sites with a robust history of conducting , particularly within the . Statistics reveal that sites with extensive experience boast a higher success rate in effectively navigating challenges and delivering reliable results. For instance, recent data indicates that experienced sites in Peru have achieved a compared to their less experienced counterparts.
• Participant Population: A thorough analysis of the local community’s demographics is essential to ensure access to the target participant group for your study. Understanding the demographic landscape is crucial for . By 2025, the demographics show an increasing number of individuals with conditions pertinent to , rendering it an attractive site for clinical research.
• Infrastructure: Assessing the site’s facilities is vital, ensuring they are equipped with necessary medical equipment and staffed by qualified personnel. A well-equipped location can significantly enhance testing efficiency and patient safety.
• : It is critical to verify that the site adheres to local regulations and maintains a solid track record of successful audits by regulatory bodies. This compliance is essential for preserving the integrity of the experiment and facilitating smoother approval processes.

As Jason Hannon, President and CEO of Mainstay Medical, asserts, “We have real-world data showing that when you turn this therapy loose, physicians will be able to get the same results.” This statement underscores the necessity of selecting sites capable of delivering reliable outcomes.

Utilizing resources such as (REPEC) can assist in identifying suitable sites and streamlining the selection process. Engaging with local experts and stakeholders early in the planning phase can further enhance site selection. A case study involving Mainstay Medical illustrates that by collaborating with medical directors from various payers and developing studies based on their feedback, the team significantly improved study results. This proactive engagement resulted in a higher likelihood of successful reimbursement and market acceptance.

By concentrating on these critical factors and leveraging the expertise of , a leader in Medtech research in Latin America, recognized for its collaboration with Caribbean Health Group to enhance , you can optimize .

Engage Local Stakeholders for Enhanced Recruitment

To enhance , implementing the following strategies for engaging local stakeholders is essential:

• Collaboration with Healthcare Providers: Establish partnerships with local hospitals and clinics to identify potential participants and secure their support. This partnership not only enhances access to a broader group of individuals but also fosters trust within the community. As Arthur Conan Doyle noted, “,” underscoring the importance of data-driven approaches in recruitment efforts.
• : Arrange informational sessions and workshops focused on educating the community regarding the initiative’s objectives and advantages. Addressing concerns directly can alleviate apprehensions and foster a supportive environment for participation. The case study on “” illustrates how engaging with communities can lead to better health outcomes and increased participation.
• : Engage with organizations that represent patient interests to broaden outreach efforts and enhance credibility. These groups can assist in connecting researchers and potential participants, ensuring that the study resonates with the community.
• : Leverage local newspapers, radio, and social media platforms to disseminate information about the proceedings and its significance. Effective communication through these channels can raise awareness and encourage participation. Significantly, Clinical Leader has underscored the , stressing the role of local media in promoting community involvement. Furthermore, 16% of clinical studies are classified as ‘Other,’ emphasizing the variety of study types and the necessity for customized recruitment strategies.
• Incorporate Technology: Implement for among stakeholders of the study. This not only improves data integrity but also fosters trust, which is crucial for patient recruitment. bioaccess® is committed to ensuring information security and client trust, addressing any concerns through established grievance and data protection procedures.

The Medtech clinical trial strategies in Peru can greatly enhance recruitment and retention rates, ensuring that studies are conducted efficiently and effectively. By nurturing strong connections with healthcare providers and the community, clinical studies can achieve improved results and aid in advancing medical knowledge.

Incorporate Cultural Insights into Trial Design

Integrating cultural insights into is essential for enhancing participation and ensuring positive outcomes. The key strategies include:

• : Conducting thorough research on the cultural beliefs and practices of the target population is imperative. This understanding ensures that the trial design is respectful and relevant, fostering trust among potential participants. As Alam W. Watts pointed out, we often consider the languages and visuals presented by our society, highlighting the importance of understanding these influences on individuals’ perceptions. Steve Garchow’s experience underscores that a deep understanding of local healthcare practices and patient needs is vital for effective engagement in .
• Tailoring Communication: Utilizing when interacting with participants is crucial. This approach not only enhances comprehension but also fosters connection, making individuals feel valued and acknowledged. Garchow’s insights on the necessity for further emphasize the importance of this approach in .
• : Developing study protocols that allow for adaptability in participation is essential. Adjusting to can significantly enhance comfort and willingness to engage in the study. Garchow’s emphasis on the need for local groups to modify global strategies to meet specific country requirements reinforces this approach.
• : Establishing avenues for participants to provide input on the process is vital. Actively listening to their feedback ensures that their voices are heard and considered, resulting in a more inclusive and responsive testing environment. The importance of local engagement, as highlighted by Garchow, strengthens the value of incorporating participant feedback into study design.

The significance of is further illustrated by case studies, such as those demonstrating partnerships in African studies, which confirm that effective collaboration with local leaders and health workers is essential for . By integrating these cultural factors and addressing barriers to participation, researchers can cultivate a more inclusive environment that enhances , promotes engagement, and ultimately improves the quality and efficacy of research studies.

Implement Targeted Patient Recruitment Strategies

To effectively implement targeted in Peru, consider the following approaches:

• Digital Campaigns: Leverage social media and online platforms to engage potential participants, particularly younger demographics who are more active online. Effective digital campaigns can significantly improve visibility and interest in medtech . Notably, , indicating a strong existing engagement that can be tapped into.
• Community Engagement: Organize local events to raise awareness about the trial and its benefits, fostering personal connections with potential contributors. This strategy not only builds trust but also encourages community involvement, which is crucial for successful recruitment. The case study titled “” emphasizes the importance of outreach and educational resources in building trust and improving engagement in research activities.
• Referral Programs: Encourage existing members to refer friends and family, leveraging personal networks to enhance recruitment efforts. This approach can create a sense of community and shared purpose among participants.
• Incentives: Provide incentives for participation, such as , to encourage enrollment. These incentives can significantly increase participation rates by addressing common barriers to entry.

Moreover, the partnership between bioaccess™ and Caribbean Health Group to establish Barranquilla as a premier location for research studies highlights the importance of Medtech and the significance of . By providing extensive —including feasibility assessments, site selection, compliance evaluations, study setup, import permits, project management, and reporting—researchers can ensure studies are sufficiently powered to produce significant results. play an essential role in this process, as emphasized in the case study “,” which demonstrates how their established connections within various populations can enhance research and improve health equity. As Dr. Eric Topol noted, “The crowd will see you now, the patient will see you now… Everyone but the doctor,” emphasizing the importance of patient visibility in .

Conclusion

Navigating the regulatory framework for clinical trials in Peru is essential for researchers aiming for successful outcomes. Understanding the Clinical Trials Law, the role of ethics committees, and the submission process is fundamental to ensuring compliance and maintaining public trust. With recent updates designed to streamline these processes, staying informed is critical for effective trial initiation.

Selecting optimal clinical sites is equally important, requiring careful consideration of site experience, patient demographics, infrastructure, and regulatory compliance. Engaging local stakeholders, including healthcare providers and community organizations, can significantly enhance patient recruitment efforts, fostering trust and participation.

Incorporating cultural insights into trial design further enriches the research process, ensuring that trials are respectful and relevant to local populations. Implementing targeted recruitment strategies, such as digital campaigns and community engagement, can also drive participation.

Ultimately, the success of clinical trials in Peru hinges on a holistic approach that combines regulatory knowledge, strategic site selection, stakeholder engagement, cultural sensitivity, and innovative recruitment strategies. By leveraging these elements, researchers can enhance the likelihood of achieving successful trial outcomes, contributing to the advancement of medical knowledge and public health in this vibrant market.

Frequently Asked Questions

What governs the research study environment in Peru?

The research study environment in Peru is primarily governed by the National Institute of Health (INS), which is responsible for the authorization and oversight of research investigations.

What is the Research Studies Law in Peru?

The Research Studies Law establishes the framework for conducting research studies, emphasizing ethical considerations and safety protocols for participants. It was ratified through Supreme Decree No 021-2017-SA and includes stringent requirements for ethical oversight and patient safety.

What role do Ethics Committees play in clinical studies in Peru?

All clinical studies in Peru require review and approval from an accredited ethics committee to safeguard the rights and well-being of participants and to ensure that ethical standards are upheld throughout the research process.

What is the submission process for researchers in Peru?

Researchers must submit comprehensive documentation, including detailed protocols, informed consent forms, and safety reporting plans, to the INS for approval before commencing any study, ensuring compliance with regulatory standards.

What recent updates have been made to the regulatory framework in Peru?

In 2025, new guidelines were introduced to streamline the approval procedure, potentially reducing timelines for initiation of research studies.

How can bioaccess® assist researchers in Peru?

Bioaccess® provides expertise in navigating regulations, particularly concerning the submission process and collaboration with ethics committees. They offer services such as feasibility assessments, site selection, and project management to support successful Medtech clinical trial strategies in Peru.

What is the importance of participant population analysis in clinical trials?

Analyzing the local community’s demographics is essential for ensuring access to the target participant group for the study, which is crucial for recruitment and retention.

What factors should be evaluated when selecting clinical trial sites in Peru?

Key factors include site experience, participant population demographics, infrastructure, and regulatory compliance to ensure successful outcomes.

Why is site experience important in clinical trials?

Sites with a robust history of conducting clinical trials, especially in the Medtech sector, have a higher success rate in navigating challenges and delivering reliable results.

How can the Peruvian Clinical Trials Registry (REPEC) assist in site selection?

The REPEC can help identify suitable clinical trial sites and streamline the selection process, enhancing the likelihood of successful outcomes.

What is the significance of engaging local experts in the planning phase of clinical trials?

Engaging local experts and stakeholders early in the planning phase can improve study results and increase the likelihood of successful reimbursement and market acceptance.

List of Sources

1. Navigate Peru’s Regulatory Framework for Clinical Trials
   • ibanet.org (https://ibanet.org/clinical-trials-peru)
   • statista.com (https://statista.com/statistics/1560023/clinical-trials-by-status-peru)
2. Choose Optimal Clinical Sites for Your Trials in Peru
   • massdevice.com (https://massdevice.com/how-to-design-medtech-clinical-trials-that-deliver)
   • statista.com (https://statista.com/statistics/1560023/clinical-trials-by-status-peru)
   • blog.bioaccessla.com (https://blog.bioaccessla.com/best-practices-for-effective-clinical-trial-design-for-medtech-insights-from-industry-experts)
3. Engage Local Stakeholders for Enhanced Recruitment
   • Clinical Trials Statistics and Facts (2026) (https://media.market.us/clinical-trials-statistics)
   • ey.com (https://ey.com/en_us/insights/life-sciences/how-a-community-based-approach-can-improve-clinical-trial-diversity)
   • qualtrics.com (https://qualtrics.com/blog/research-quotes)
4. Incorporate Cultural Insights into Trial Design
   • monash.edu (https://monash.edu/medicine/news/latest/2025-articles/painting-a-bigger-picture-the-importance-of-cultural-diversity-in-clinical-trials)
   • 19 Insightful Quotes About Culture | Textappeal (https://textappeal.com/cultureshocks/insightful-quotes-about-culture)
   • orrbitt.com (https://orrbitt.com/news/cultural-diversity-clinical-trials)
   • fhiclinical.com (https://fhiclinical.com/cultural-competence-in-research)
5. Implement Targeted Patient Recruitment Strategies
   • www2.deloitte.com (https://www2.deloitte.com/us/en/insights/industry/health-care/community-based-inclusive-and-equitable-clinical-trials.html)
   • mobihealthnews.com (https://mobihealthnews.com/content/77-2015s-most-interesting-digital-health-quotes)
   • digitalismedical.com (https://digitalismedical.com/blog/seo-quotes)

Introduction

As the landscape of clinical research continues to evolve, Latin America emerges as a pivotal player in the global arena. This region, rich in diverse populations and unique healthcare challenges, offers a fertile ground for innovative clinical trials that can yield significant insights and advancements in medical science. Recent collaborations and strategic initiatives underscore Latin America’s commitment to enhancing its clinical research capabilities, positioning countries like Colombia, Brazil, and Mexico at the forefront of this endeavor.

With robust regulatory frameworks and a growing network of Contract Research Organizations, the region is not only attracting international interest but also addressing pressing health issues such as cancer and diabetes. This article delves into the key characteristics, challenges, and opportunities within Latin America’s clinical research sector, shedding light on the vital roles played by stakeholders and the importance of regulatory compliance in fostering a thriving research environment.

Overview of Clinical Research in Latin America: Key Characteristics and Contributions

Investigative studies in Latin regions have positioned themselves as a crucial component of and the worldwide testing framework. The varied inhabitants of the area are a significant asset for , enhancing the quality and relevance of the findings. Recent partnerships, like the one between bioaccess™ and Caribbean Health Group, aim to establish Barranquilla as a premier location for , with the backing of Colombia’s Minister of Health.

This collaboration provides extensive management services for studies, including:

• Feasibility assessments
• Compliance evaluations
• Setup
• Import permits
• Project management
• Reporting

These services are essential for enhancing processes. Brazil, Mexico, and Argentina remain key players in the field of , bolstered by robust regulatory frameworks and an expanding network of (CROs) that facilitate regulatory compliance and optimize patient recruitment. In 2023, accounted for 3.5% of the worldwide medical study matching software market, highlighting the area’s importance in medical research.

Mariana Bei, Sr. Director of Clinical Operations and Brazil GMBA at Parexel, notes that having a with local talent and regulatory authorities. The rising occurrence of illnesses such as cancer and diabetes in Latin regions further emphasizes the necessity for , particularly in high-prevalence locations like gastric carcinoma in Chile and Peru. Moreover, progress in health technology, including recent , is crucial for improving the efficiency and effectiveness of medical studies.

This local expertise and collaborative spirit position the region as an increasingly appealing destination for pharmaceutical firms seeking to enhance their capabilities through while adhering to international quality standards. Notably, the collaboration has achieved over a 50% reduction in recruitment time and impressive 95% retention rates, demonstrating the effectiveness of the initiatives undertaken.

Challenges and Opportunities in Conducting Clinical Trials in Latin America

presents a distinctive blend of challenges and opportunities that require careful navigation. One significant hurdle is the diverse regulatory environments across various countries, which can result in delays and escalate costs. In Colombia, the INVIMA (National Food and Drug Surveillance Institute) plays a crucial role as a Level 4 health authority, overseeing and ensuring compliance with international standards.

Colombia has acknowledged the advantages of enhancing , as demonstrated by its ambitious aimed at becoming a knowledge economy. This commitment aligns with , promoting adherence to best practices in . Furthermore, the new Colombian R&D tax credit enables small and midsize companies to claim a 50% tax credit on R&D and innovation projects, offering a in the region.

Cultural nuances also play a critical role, influencing ; tailoring approaches to effectively engage local populations is essential for success, particularly in understanding the local healthcare landscape and patient expectations.

Despite these challenges, the advantages of are compelling. The area provides , making it an appealing choice for sponsors looking to carry out studies effectively. Furthermore, the availability of enhances the potential for meaningful outcomes.

Recent developments, such as to collaborate with local manufacturers, highlight the market’s value, estimated at $1.42 billion. The increasing investment in healthcare facilities, along with the skills of local study groups, is poised to enhance the region’s ability to carry out successful medical evaluations in the future. As demonstrated by the fact that 52% of worldwide medical studies are now performed outside the U.S., is emerging as a favored location due to simpler recruitment, reduced expenses, and enthusiastic investigators in nations with universal healthcare systems, highlighting its crucial role in the global medical investigation landscape.

To ensure comprehensive study management, our services encompass:

• Feasibility studies
• Site selection
• Compliance reviews
• Setup
• Import permits
• Project management

All tailored to meet the unique regulatory requirements of each country.

Regulatory Framework Governing Clinical Research in Latin America

The regulatory framework for is characterized by significant diversity, with each country establishing its own set of regulations and overseeing bodies. In Brazil, the National Health Surveillance Agency (ANVISA) plays a crucial role in regulating research studies, ensuring adherence to ethical standards, informed consent, and . Conversely, Mexico relies on the Federal Commission for Protection against Sanitary Risk (COFEPRIS) for similar oversight.

Grasping these regulations is essential for sponsors and Contract Research Organizations (CROs) seeking to navigate the intricacies of effectively.

In Colombia, the is especially advantageous for carrying out due to its extensive management services, which encompass:

• Feasibility assessments
• Site selection
• Compliance evaluations
• Study setup
• Import permits
• Project management
• Reporting

A critical aspect of these services is the to ensure compliance with country requirements. The country offers , along with faster approval times, typically requiring only 90-120 days for the IRB/EC and INVIMA reviews.

Colombia’s healthcare system has been ranked 22nd globally by the World Health Organization, further enhancing its reputation as a high-quality destination for .

With a population exceeding 50 million, Colombia provides robust , supported by universal healthcare coverage for about 95% of its citizens. This extensive coverage facilitates access to a diverse patient population, which is essential for , making recruitment more efficient. Furthermore, the nation provides , making it an appealing option for project sponsors.

As Julio G. Martinez-Clark, CEO of bioaccess, notes, ‘Colombia has recognized these benefits and has an ambitious science, technology, and innovation plan for 2022–2031 to become a knowledge economy.’ Such initiatives exemplify the commitment to fostering that supports . Furthermore, it is essential for researchers and sponsors to confirm they have read the privacy policy before submitting any applications, as this is a critical aspect of regulatory compliance.

Lastly, the reporting process, including tracking study status and documenting serious and non-serious adverse events, is vital for maintaining transparency and accountability throughout the study.

The Role of Stakeholders in Clinical Research: Collaborations and Partnerships

Stakeholders are pivotal in shaping the success of . The intricate nature of conducting necessitates robust collaborations among:

• Pharmaceutical companies
• Academic institutions
• Regulatory bodies

For instance, during a gathering on March 29, 2019, in Miami, FL, the partnership between bioaccess™ and was revealed, intending to position Barranquilla as a prominent location for research studies.

Colombia’s Minister of Health, Juan Pablo Uribe, attended this meeting and highlighted the initiative’s significance for improving , stating, ‘This collaboration is crucial for advancing our and attracting global research projects to the region.’ Such partnerships not only facilitate knowledge sharing but also optimize resources and ensure compliance with . Engaging local universities significantly enhances , utilizing their established networks and community trust.

Furthermore, as Dushyanth Surakanti, Founder & CEO of Sparta Biomedical, noted regarding his experience with bioaccess® during its first human study in Colombia, these collaborations have resulted in substantial improvements, including and 95% retention rates. Involving regulatory authorities early in the study design process enables the identification of potential hurdles and simplifies the approval process. As Natalie Gershman, CEO and medical director of Geny Research, states, ‘This relationship significantly helps to increase subject enrollment and retention rates, and .’

A case study titled ” illustrates how local engagement and the use of telemedicine are streamlining patient recruitment, thereby creating opportunities for targeted trials in , especially for diseases prevalent in the region. According to Statista, the number of registered research studies by country reflects the growing importance of collaborations in this landscape. As the environment for evolves, particularly with the rise of digital health technologies and a focus on personalized medicine, fostering strong relationships among stakeholders will be critical.

These collaborations will not only advance research initiatives but also contribute to improved patient outcomes in the region.

Conclusion

Latin America’s clinical research landscape is increasingly recognized for its unique contributions and opportunities within the global framework. The region’s diverse populations and pressing health challenges provide an ideal environment for innovative clinical trials, particularly in countries like Colombia, Brazil, and Mexico. Recent collaborations have demonstrated the potential for significant advancements in medical science, with partnerships optimizing trial management processes and enhancing patient recruitment and retention.

While challenges such as regulatory diversity and cultural nuances exist, the advantages of conducting trials in Latin America are compelling. Lower operational costs, access to treatment-naïve patient populations, and a commitment to improving healthcare infrastructure position the region as an attractive destination for pharmaceutical companies. The supportive regulatory environment, exemplified by Colombia’s initiatives and incentives, further enhances the feasibility of conducting successful clinical trials.

As the clinical research environment continues to evolve, the role of stakeholders—including pharmaceutical companies, Contract Research Organizations, academic institutions, and regulatory bodies—will be critical. Effective collaborations and partnerships will not only facilitate compliance with regulations but also streamline processes and improve patient outcomes. Emphasizing the importance of local engagement and leveraging advancements in health technology will be vital for realizing the full potential of clinical research in Latin America, ensuring the region’s pivotal role in advancing global medical science.

Frequently Asked Questions

Why are investigative studies important in Latin America?

Investigative studies are crucial in Latin America as they enhance the quality and relevance of clinical research findings due to the region’s diverse population.

What recent partnerships have been established to promote clinical research in Latin America?

A notable partnership is between bioaccess™ and Caribbean Health Group, aimed at establishing Barranquilla as a premier location for clinical research with support from Colombia’s Minister of Health.

What management services are provided through this collaboration?

The collaboration offers extensive management services including feasibility assessments, site selection, compliance evaluations, setup, import permits, project management, and reporting.

Which countries are key players in clinical research in Latin America?

Brazil, Mexico, and Argentina are key players, supported by strong regulatory frameworks and a growing network of Contract Research Organizations (CROs).

What percentage of the worldwide medical study matching software market did clinical research in Latin America account for in 2023?

Clinical research in Latin America accounted for 3.5% of the worldwide medical study matching software market in 2023.

How does having a local presence benefit clinical research operations?

A local presence strengthens relationships with local talent and regulatory authorities, which is beneficial for conducting clinical research.

What health issues underscore the necessity for clinical research in Latin America?

The rising occurrence of illnesses such as cancer and diabetes, particularly in high-prevalence areas like gastric carcinoma in Chile and Peru, emphasizes the need for clinical research.

How does progress in health technology impact clinical research in the region?

Advances in health technology, including recent eHealth data for Chile, improve the efficiency and effectiveness of medical studies.

What are the results of the collaboration in terms of recruitment and retention rates?

The collaboration has achieved over a 50% reduction in recruitment time and impressive 95% retention rates, demonstrating the effectiveness of the initiatives undertaken.

List of Sources

1. Overview of Clinical Research in Latin America: Key Characteristics and Contributions
   • Clinical Trials in Latin America (https://languageconnections.com/clinical-trials-in-latin-america)
   • parexel.com (https://parexel.com/insights/article/latam-a-model-for-fsp-success)
   • statista.com (https://statista.com/statistics/911464/health-information-availability-latin-america-country)
   • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-matching-software-market/latin-america)
2. Challenges and Opportunities in Conducting Clinical Trials in Latin America
   • meddeviceonline.com (https://meddeviceonline.com/doc/colombia-a-strategic-choice-for-medtech-clinical-trials-0001)
   • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
3. Regulatory Framework Governing Clinical Research in Latin America
   • statista.com (https://statista.com/statistics/1013599/latin-america-clinical-trials)
   • Latin America Clinical Trials Market Size & Outlook, 2033 (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/latin-america)
   • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
4. The Role of Stakeholders in Clinical Research: Collaborations and Partnerships
   • statista.com (https://statista.com/statistics/1013599/latin-america-clinical-trials)
   • blog.bioaccessla.com (https://blog.bioaccessla.com/how-to-leverage-clinical-research-for-successful-market-entry-in-latin-america)
   • blog.bioaccessla.com (https://blog.bioaccessla.com/what-is-a-latin-america-cro-understanding-their-role-in-clinical-research)

Introduction

In the dynamic field of medical device trials, grasping the foundational principles and best practices is imperative for guaranteeing the safety and efficacy of new technologies. The clinical research landscape is continually evolving, shaped by regulatory frameworks, technological advancements, and diverse patient populations. As organizations endeavor to navigate these complexities, strict adherence to guidelines such as Good Clinical Practice (GCP) and ISO 14155:2020 becomes essential. The integration of robust methodologies, effective data management, and proactive risk assessment not only enhances trial outcomes but also cultivates trust among stakeholders.

This article investigates the key elements that define successful medical device trials, examining the challenges and opportunities within the Latin American context, and highlighting the innovative strategies poised to propel the industry forward.

Fundamentals of Medical Device Trials: Key Principles and Practices

Medical device evaluations are governed by . These principles are foundational to the success of clinical research and include:

1. : Adhering to GCP guidelines is paramount for maintaining the integrity of . This includes ensuring informed consent, protecting participant rights, and safeguarding information integrity. In 2025, adherence to GCP remains a critical focus, with recent statistics indicating that 45% of information from leading organizations is entered on the same day as the visit date. This statistic highlights the dedication to prompt and precise data management, which is essential for preserving data integrity in research studies.
2. : A thorough understanding of local and international regulations is crucial for the successful execution of the study. Familiarity with the requirements set forth by regulatory bodies such as the FDA and EMA is essential. In Colombia, for instance, the INVIMA (National Food and Drug Surveillance Institute) plays a pivotal role in overseeing , classified as a Level 4 health authority by PAHO/WHO. ; it directly influences the approval process and the overall success of medical devices in the market. The era of EHR-facilitated PCTs offers a chance for reappraisal and redesign of research conduct, enhancing and .
3. : Identifying and mitigating risks associated with studies is vital for participant safety and study integrity. Conducting comprehensive risk assessments and implementing strategies to minimize potential adverse effects are key components of effective . Recent case studies emphasize the significance of proactive in improving outcomes and participant safety. Utilizing registries, like SWEDEHEART for cardiac patients, can offer valuable information for and enhance the overall quality of clinical studies.
4. Information Management: Efficient information gathering and management methods are essential to guarantee the dependability of test outcomes. Employing validated data collection tools and maintaining precise records throughout the process are critical. , illustrate the benefit of utilizing existing registries for patient enrollment and endpoint collection, improving the relevance of results to real-world medical practice.

Integrating these principles into the design and implementation of medical device studies not only aligns with the best practices for medical device trials but also promotes a culture of excellence in research. As Ashley Davidson, vice president of product lead – sponsor tech strategy, noted, “We need more site-centric approaches in project startup,” emphasizing the importance of participant engagement and site management. Additionally, extensive management services provided by bioaccess, encompassing feasibility studies, site selection, compliance reviews, setup, import permits, project management, and reporting, enable the successful execution of studies.

As the landscape of research trials evolves, embracing these foundational elements will be essential for advancing medical technology and improving patient outcomes, while also contributing to local economies through job creation and healthcare improvement.

Navigating Regulatory Frameworks: Understanding ISO 14155:2020

outlines essential requirements and , encompassing the design, conduct, recording, and reporting of investigations involving medical devices. Its key components are critical for ensuring the integrity and success of clinical trials:

1. Research Design: A robust research design is fundamental, addressing the specific objectives of the investigation while prioritizing . A well-structured design significantly enhances the reliability of outcomes and facilitates . bioaccess® specializes in managing various research types, including (EFS), (FIH), Pilot Trials, Pivotal Trials, and Post-Market Clinical Follow-Up Trials (PMCF), ensuring that each trial is tailored to meet the highest standards of quality and compliance. With over 20 years of experience in Medtech, bioaccess® brings a wealth of knowledge to each project, enhancing the likelihood of successful outcomes.
2. Informed Consent: The standard mandates comprehensive , ensuring participants are thoroughly educated about the study’s purpose, procedures, potential risks, and benefits prior to participation. This transparency is vital for ethical compliance and fosters trust between researchers and participants. bioaccess® emphasizes informed consent as a cornerstone of , enhancing participant engagement and retention.
3. Information Integrity: Ensuring the precision, completeness, and verifiability of information gathered during studies is a cornerstone of . This requirement is crucial for maintaining the reliability of research results, ultimately influencing the acceptance of medical devices in the market. With over 20 years of experience in Medtech, bioaccess® applies stringent data management practices to maintain throughout the study process.
4. Ethical Considerations: Adherence to is non-negotiable. The formation of an independent ethics committee to supervise the study is a critical element, ensuring that all ethical considerations are addressed throughout the research. bioaccess® partners with local health authorities, including INVIMA, to ensure adherence to and regulatory obligations, positioning Barranquilla as a premier destination for research studies in Latin America.

In 2025, compliance with has become increasingly significant, as demonstrate that adherence to these guidelines enhances the quality of research investigations. Organizations implementing these standards report marked improvements in participant retention rates, attributed to the emphasis on informed consent and ethical practices. Notably, over 200,000 medical device professionals are now part of a community that recognizes the importance of these standards.

Examples show that businesses utilizing not only optimize their testing procedures but also achieve quicker market access for their medical devices, emphasizing and the standard’s influence on overall trial success. One such case study, titled “Application of ISO 14155 in Post-Market Activities,” illustrates the practical application of the standard across different stages of the product lifecycle, providing clear guidance on its implementation.

Furthermore, bioaccess® has played a crucial role in assisting Medtech startups, demonstrating how customized research services can promote the development of medical devices. As Jon Ingi Bergsteinsson, co-founder of Greenlight Guru Clinical, noted, “He paved the way for the platform’s quality standards, data security, and compliance,” emphasizing the critical nature of these elements in trials.

Additionally, the recent guidance from MDCG 2024-3 highlights the need for justification based on the state of the art of medical practice, reinforcing the relevance of in today’s research landscape.

Designing Effective Clinical Investigations: Best Practices and Essential Traits

Designing necessitates meticulous planning and attention to several critical factors.

• : Establishing specific, measurable objectives is paramount for guiding both the study design and subsequent analysis. A well-defined objective not only clarifies the purpose of the study but also aligns the research with regulatory expectations, ultimately enhancing the likelihood of success. This emphasis on clear goals is a foundation of ‘s strategy, ensuring that Medtech startups can manage the intricacies of research processes effectively.
• Robust Methodology: Choosing a suitable research design—such as randomized controlled experiments or cohort analyses—is essential. The chosen methodology must align with the research objectives and comply with regulatory requirements, ensuring that the investigation is both scientifically sound and ethically conducted. specializes in extensive , including feasibility studies and compliance evaluations, to support this process.
• : Performing a power analysis is crucial to determine the necessary sample size for achieving . This step is essential, as inadequate sample sizes can lead to inconclusive findings, undermining the study’s validity and potential impact on clinical practice.
• Endpoint Selection: Clearly defining primary and secondary endpoints that are clinically relevant and reliably measurable is essential. This clarity not only facilitates data collection and analysis but also ensures that the outcomes are meaningful to stakeholders, including regulatory bodies and healthcare providers.
• : Carrying out can be crucial for assessing the practicality of the design. These preliminary investigations allow researchers to identify potential challenges and make necessary adjustments before launching the full-scale trial, thereby increasing the chances of success. ‘s expertise in Early-Feasibility and exemplifies this proactive approach.

In 2025, the focus on is expected to intensify as clinical end-markets become increasingly crowded. Companies are already assessing site experiences by tracking entry efficiency, which has revealed that a significant portion of information is entered on the same day as the visit date. This efficiency not only streamlines processes but also enhances patient care through improved data management. Moreover, the incorporation of in research studies has the potential to shorten study timelines by up to 30% and decrease expenses by as much as 20%. These advancements highlight the significance of embracing best practices in research methodology to enhance outcomes and foster innovation in the medical device sector.

utilizes such advancements to enhance their research services, assisting Medtech companies in improving site experiences and effectively navigating the crowded market. Furthermore, the partnership between and Caribbean Health Group seeks to establish Barranquilla as a premier location for research studies in Latin America, backed by Colombia’s Minister of Health, which further highlights the strategic significance of these best practices.

The Role of Monitoring and Oversight in Clinical Trials

Monitoring and oversight stand as essential pillars in , ensuring strict adherence to protocols and regulatory standards. Effective strategies encompass several key practices:

1. : Frequent site visits are crucial for assessing compliance with study protocols, reviewing data accuracy, and ensuring participant safety. Statistics reveal that can significantly diminish the incidence of protocol deviations, thereby enhancing the overall quality of the study. For instance, the suggests that a minimum of three visits is recommended to effectively manage and mitigate risks associated with research sites. that incorporate these , ensuring comprehensive supervision of all study aspects.
2. Information Validation: Establishing robust procedures to confirm the precision and thoroughness of information gathered during experiments is vital. This includes cross-checking entries and employing advanced statistical methods, such as regression analysis, to identify discrepancies. A recent case analysis demonstrated that utilizing a combination of tree-based models and can effectively forecast clinical study duration, underscoring the significance of in optimizing timelines. This analysis revealed varying degrees of correlation between complexity and duration across different phases, offering insights into the factors influencing both duration and complexity. At bioaccess, we prioritize data verification as part of our commitment to regulatory excellence and quality assurance.
3. : Establishing clear procedures for reporting and managing adverse events is critical for safeguarding participant safety and maintaining study integrity. In 2025, the emphasis on has intensified, with underscoring the necessity for prompt and clear communication regarding any incidents occurring during the study. Bioaccess ensures meticulous documentation and reporting of all adverse events in compliance with local regulations, including those mandated by INVIMA, the Colombian National Food and Drug Surveillance Institute.
4. : Active oversight by sponsors is essential to ensure compliance with regulatory standards and adherence to best practices in medical device trials. This includes regular assessments of site performance and participant safety, which are fundamental for preserving the trial’s credibility. As noted by the Head of Clinical Information Engineering, “Traditionally, information management was outsourced to our CRO vendor partners.” The initiative aims to bring all research in-house, enabling our internal teams to engage more directly. This approach allows us to operationalize studies internally, take control of our data, and deliver high-quality outcomes for our patients. Expert opinions emphasize that best practices for medical device trials, including , can lead to improved outcomes and enhanced trust in the research process. At bioaccess, our skilled Clinical Study Managers, such as Oswaldo Amaya, MD, and Dr. Sergio Alvarado, are dedicated to ensuring that all studies are conducted with the utmost integrity and compliance.

By implementing best practices for medical device trials, research studies can achieve elevated standards of quality and safety, ultimately yielding more dependable outcomes and accelerating advancements in medical technology.

Leveraging Technology: Best Practices for eCRF in Medical Device Trials

Implementing electronic case report forms (eCRFs) in is essential for streamlining data collection and significantly enhancing data quality. At bioaccess®, we recognize that adopting can lead to improved outcomes and efficiency in research. Our comprehensive encompass feasibility assessments, site selection, compliance reviews, trial setup, import permits, project management, and reporting, ensuring that your clinical trials are conducted with the utmost expertise and care.

We specialize in various types of research, including Early-Feasibility Assessments (EFS), (FIH), Pilot Investigations, Pivotal Evaluations, and Post-Market Clinical Follow-Up Assessments (PMCF). Key strategies include:

1. User-Friendly Design: Prioritize an intuitive and easy-to-navigate interface for eCRFs. An intuitive design reduces the risk of mistakes during information input, which is essential for preserving integrity and reliability. Transparency in eCRF processes can enhance trust and loyalty among stakeholders, as studies indicate that .
2. : Utilize eCRFs that support . This capability enables prompt analysis and informed decision-making, ultimately speeding up the clinical trial process and improving responsiveness to emerging trends.
3. : Integrate within the eCRF framework. These checks can promptly identify and rectify entry errors, ensuring that the information collected is accurate and compliant with regulatory standards.
4. Integration with Other Systems: Ensure that the eCRF is compatible with other information management systems. This integration facilitates seamless information flow, reduces redundancy, and enhances overall operational efficiency. Selecting is crucial, featuring an eCRF library for reusability, regulatory compliance support, ease of use, and support for amendments and version control.

The influence of an intuitive design on eCRF quality cannot be exaggerated; research shows that 94% of customers display increased loyalty to brands that uphold transparency in their operations. Moreover, the advantages of in medical studies are underscored by recent figures, showcasing its importance in enhancing accuracy and accelerating the research process. A case study on regulatory compliance in research databases emphasizes the necessity for research databases to comply with regulatory standards set by agencies such as INVIMA, FDA, and EMA, focusing on the importance of audit trails and data traceability in ensuring data integrity.

Organizations can enhance their studies by adhering to , while promoting the development of innovative medical devices. As noted by Nelly Zental, “M.G. designed the integration between EDC and EHR and prepared the final version of the manuscript,” highlighting the importance of expert involvement in the design and implementation of eCRFs.

Challenges and Opportunities in Latin American Medical Device Trials

Conducting presents a complex landscape characterized by both challenges and opportunities.

• Regulatory Variability: The is fragmented, with each country maintaining its own set of rules and guidelines. This variability can result in delays in the approval process for research studies, as companies must navigate differing requirements and standards. For instance, the approval timelines can vary significantly, impacting the overall speed of bringing innovative medical devices to market. Bioaccess® leverages its expertise in navigating these complexities, ensuring compliance and facilitating smoother trial setups, drawing on over 20 years of experience in the Medtech industry.
• : Effective hinge on a deep understanding of cultural nuances and local practices. In countries like Peru, Chile, and Colombia, regional dialects and cultural influences can affect communication strategies. As Larissa Aviles-Santa, Director of the Division of Health Services Research, emphasizes, understanding local idioms is crucial to avoid misunderstandings in health research. Customizing recruitment strategies to connect with local communities is vital for improving participant involvement and guaranteeing the success of trials.
• Cost-Effectiveness: Latin America stands out as a . The operational costs in this region are generally lower than those in North America and Europe, making it an attractive option for Medtech companies looking to optimize their budgets while maintaining . This economic benefit enables broader research and quicker patient recruitment, further backed by , which consist of feasibility assessments, site selection, and project oversight.
• : The region’s rich diversity in patient demographics offers a unique opportunity to gather insights into the safety and efficacy of medical devices across various populations. This diversity can enhance the generalizability of study results, providing valuable data that can inform future product development and regulatory submissions. Bioaccess’s partnership with Caribbean Health Group seeks to establish Barranquilla as a prominent location for medical studies, further boosting the region’s attractiveness for Medtech research.

In 2022, the research landscape experienced around 106 and a total of 2,478 phase-I interventional studies, underscoring the strong activity in this sector. The oncology segment, in particular, has been a focal point, driven by the increasing prevalence of cancer and the demand for innovative treatments. The findings indicate that economic, population, and regulatory factors significantly affect the geographical distribution of research studies.

As the need for research trials continues to grow, understanding the specific challenges and opportunities in Latin America will be essential for applying the best practices for and ensuring successful trial execution and product advancement. Bioaccess® specializes in various study types, including Early-Feasibility Studies, First-In-Human Studies, Pilot Studies, Pivotal Studies, and Post-Market Clinical Follow-Up Studies (PMCF), ensuring a comprehensive approach to clinical research.

Conclusion

In the intricate realm of medical device trials, understanding and implementing key principles and best practices is crucial for ensuring the safety and efficacy of new technologies. Adherence to Good Clinical Practice (GCP) and ISO 14155:2020 guidelines not only safeguards participant rights but also enhances data integrity and regulatory compliance. As highlighted throughout the article, effective risk management, robust data management, and a well-structured study design are fundamental elements that contribute to successful trial outcomes.

Navigating the unique challenges and opportunities within the Latin American context further emphasizes the significance of cultural considerations and regulatory variability. The region’s diverse patient populations provide a rich landscape for gathering valuable insights, while its cost-effectiveness presents an attractive alternative for conducting clinical trials. Organizations like bioaccess continue to leverage their expertise in these areas, creating substantial potential for innovation and advancement in medical technology.

Ultimately, the integration of these foundational elements fosters excellence in clinical research and cultivates trust among stakeholders. By prioritizing these best practices and embracing the evolving landscape of clinical trials, organizations can enhance their capabilities, drive innovation, and contribute to improved patient outcomes and local economies. As the medical device industry continues to evolve, a commitment to excellence in trial design and execution will be paramount for achieving sustainable success.

Frequently Asked Questions

What are the essential principles governing medical device evaluations?

The essential principles include Good Clinical Practice (GCP), Regulatory Compliance, Risk Management, and Information Management, which ensure the safety and efficacy of medical devices being tested.

What is Good Clinical Practice (GCP) and why is it important?

GCP refers to guidelines that maintain the integrity of clinical trials, ensuring informed consent, participant rights protection, and information integrity. Adherence to GCP is critical for data management and the overall success of clinical research.

How does regulatory compliance affect clinical studies?

Regulatory compliance ensures a thorough understanding of local and international regulations, which influences the approval process and success of medical devices in the market. Compliance with bodies like the FDA, EMA, and INVIMA is essential.

What role does risk management play in medical device studies?

Risk management involves identifying and mitigating risks to ensure participant safety and study integrity. Comprehensive risk assessments and strategies to minimize potential adverse effects are vital for successful studies.

Why is information management crucial in clinical trials?

Efficient information management guarantees the reliability of test outcomes. Employing validated data collection tools and maintaining accurate records are essential for achieving trustworthy results in clinical research.

What is ISO 14155:2020, and what does it encompass?

ISO 14155:2020 outlines essential requirements and best practices for medical device trials, covering the design, conduct, recording, and reporting of investigations to ensure the integrity and success of clinical trials.

How does research design impact clinical trials?

A robust research design addresses specific study objectives while prioritizing participant safety, enhancing the reliability of outcomes and facilitating regulatory approval.

What is the significance of informed consent in clinical studies?

Informed consent ensures participants are fully educated about the study’s purpose, procedures, risks, and benefits, fostering trust and ethical compliance in research.

How does information integrity affect research results?

Ensuring the precision, completeness, and verifiability of information is crucial for maintaining the reliability of research results, influencing the acceptance of medical devices in the market.

What ethical considerations are involved in medical device trials?

Adherence to ethical standards is essential, including the formation of an independent ethics committee to oversee studies and ensure all ethical considerations are addressed.

How has ISO 14155:2020 impacted participant retention rates?

Organizations implementing ISO 14155:2020 report improvements in participant retention rates due to its emphasis on informed consent and ethical practices.

What advantages do businesses gain from implementing ISO 14155:2020?

Businesses that utilize ISO 14155:2020 can optimize testing procedures and achieve quicker market access for their medical devices, enhancing overall trial success.

How does bioaccess® contribute to medical device research?

Bioaccess® specializes in managing various types of research trials, ensuring compliance with high standards and enhancing the likelihood of successful outcomes through tailored services.

List of Sources

1. Fundamentals of Medical Device Trials: Key Principles and Practices
   • veeva.com (https://veeva.com/2025-clinical-data-trend-report)
   • appliedclinicaltrialsonline.com (https://appliedclinicaltrialsonline.com/view/scope-summit-2025-outlook-clinical-data)
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC4777975)
   • trialsjournal.biomedcentral.com (https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-025-08724-x)
2. Navigating Regulatory Frameworks: Understanding ISO 14155:2020
   • greenlight.guru (https://greenlight.guru/blog/iso-14155)
   • iso.org (https://iso.org/standard/71690.html)
   • greenlight.guru (https://greenlight.guru/blog/how-to-set-up-clinical-studies-to-comply-with-us-fda-regulations)
   • emergobyul.com (https://emergobyul.com/news/new-guidance-clinical-investigation-plans-medical-devices)
3. Designing Effective Clinical Investigations: Best Practices and Essential Traits
   • veeva.com (https://veeva.com/2025-clinical-data-trend-report)
   • wcgclinical.com (https://wcgclinical.com/insights/clinical-trial-trends-insights-2025)
   • novotech-cro.com (https://novotech-cro.com/articles/navigating-future-clinical-trials-expert-insights-2025)
4. The Role of Monitoring and Oversight in Clinical Trials
   • nature.com (https://nature.com/articles/s41598-024-53211-z)
   • bmcmedresmethodol.biomedcentral.com (https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-024-02261-y)
   • veeva.com (https://veeva.com/2025-clinical-data-trend-report)
5. Leveraging Technology: Best Practices for eCRF in Medical Device Trials
   • givainc.com (https://givainc.com/blog/customer-experience-statistics)
   • nature.com (https://nature.com/articles/s41746-023-00994-6)
   • klindat.com (https://klindat.com/effective-ecrf-design-a-comprehensive-guide)
6. Challenges and Opportunities in Latin American Medical Device Trials
   • globenewswire.com (https://globenewswire.com/news-release/2025/03/10/3039882/28124/en/Clinical-Trials-Market-Forecast-Report-2025-A-99-25-Billion-Industry-by-2033-Driven-by-Acceptance-of-Decentralized-Experiments-Shift-Towards-Personalized-Medicine-Demand-for-Effect.html)
   • grants.nih.gov (https://grants.nih.gov/grants/guide/pa-files/PAR-23-304.html)
   • Clinical Trials in Latin America (https://languageconnections.com/clinical-trials-in-latin-america)
   • trialsjournal.biomedcentral.com (https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-2025-1)